JP2015513902A - 計算で最適化した広い反応性を示す、ｈ５ｎ１およびｈ１ｎ１インフルエンザウイルスの抗原 - Google Patents

計算で最適化した広い反応性を示す、ｈ５ｎ１およびｈ１ｎ１インフルエンザウイルスの抗原 Download PDF

Info

Publication number
JP2015513902A
JP2015513902A JP2015503258A JP2015503258A JP2015513902A JP 2015513902 A JP2015513902 A JP 2015513902A JP 2015503258 A JP2015503258 A JP 2015503258A JP 2015503258 A JP2015503258 A JP 2015503258A JP 2015513902 A JP2015513902 A JP 2015513902A
Authority
JP
Japan
Prior art keywords
influenza
protein
vlp
virus
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503258A
Other languages
English (en)
Japanese (ja)
Inventor
テッド エム． ロス，
テッド エム． ロス，
コーリー ジェイ． クレバー，
コーリー ジェイ． クレバー，
ドナルド エム． カーター，
ドナルド エム． カーター，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2015513902A publication Critical patent/JP2015513902A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015503258A 2012-03-30 2013-03-12 計算で最適化した広い反応性を示す、ｈ５ｎ１およびｈ１ｎ１インフルエンザウイルスの抗原 Pending JP2015513902A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617815P 2012-03-30 2012-03-30
US61/617,815 2012-03-30
PCT/US2013/030530 WO2013148164A1 (en) 2012-03-30 2013-03-12 Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses

Publications (1)

Publication Number Publication Date
JP2015513902A true JP2015513902A (ja) 2015-05-18

Family

ID=49261015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015503258A Pending JP2015513902A (ja) 2012-03-30 2013-03-12 計算で最適化した広い反応性を示す、ｈ５ｎ１およびｈ１ｎ１インフルエンザウイルスの抗原

Country Status (15)

Country Link
US (2) US9212207B2 (cg-RX-API-DMAC7.html)
EP (1) EP2831094B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015513902A (cg-RX-API-DMAC7.html)
KR (1) KR20150004800A (cg-RX-API-DMAC7.html)
CN (1) CN104395336B (cg-RX-API-DMAC7.html)
AU (1) AU2013240365B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014023900A2 (cg-RX-API-DMAC7.html)
CA (1) CA2868330A1 (cg-RX-API-DMAC7.html)
HK (1) HK1203522A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN07399A (cg-RX-API-DMAC7.html)
MX (1) MX345150B (cg-RX-API-DMAC7.html)
MY (1) MY166953A (cg-RX-API-DMAC7.html)
RU (2) RU2639551C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201406153XA (cg-RX-API-DMAC7.html)
WO (1) WO2013148164A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519085A (ja) * 2018-03-28 2021-08-10 サノフィ パスツール インコーポレイテッド ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011302360B2 (en) * 2010-09-14 2015-01-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
CN106995488A (zh) 2011-06-20 2017-08-01 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原
HK1212708A1 (zh) * 2012-11-27 2016-06-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education H1n1流感的計算優化的寬反應性抗原
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
US10548965B2 (en) * 2014-12-19 2020-02-04 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
EP3233116A4 (en) * 2014-12-19 2018-05-30 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
CA2987939A1 (en) * 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
AU2016274770B2 (en) * 2015-06-09 2020-11-12 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
WO2017053413A1 (en) * 2015-09-21 2017-03-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
AU2017272344B2 (en) 2016-06-02 2022-03-03 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
IL312520A (en) * 2016-06-03 2024-07-01 Sanofi Pasteur Inc Modification of transgenic influenza hemagglutinin polypeptides
JP7329529B2 (ja) * 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
EP3773703A1 (en) 2018-04-03 2021-02-17 Sanofi Antigenic influenza-ferritin polypeptides
MX2021005257A (es) * 2018-11-06 2021-06-18 Boehringer Ingelheim Vetmedica Gmbh Composicion inmunogenica contra el subtipo h5 del virus de la influenza aviar.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506272A (ja) * 2007-11-12 2011-03-03 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア インフルエンザウイルスの複数のサブタイプに対する新規ワクチン
WO2012036993A1 (en) * 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1196788C (zh) 2000-06-23 2005-04-13 惠氏控股有限公司 野生型和嵌合流感病毒样颗粒(vlp)的装配
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007011904A2 (en) 2005-07-19 2007-01-25 Dow Global Technologies Inc. Recombinant flu vaccines
CA2633793A1 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics S.R.L. Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
WO2008091657A1 (en) * 2007-01-23 2008-07-31 Academia Sinica Flu vaccines and methods of use thereof
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
KR101956910B1 (ko) 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
US7981428B2 (en) * 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
US20120034253A1 (en) 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
WO2010036948A2 (en) * 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
DK2998315T4 (da) 2009-04-03 2022-02-07 Boehringer Ingelheim Animal Health Usa Inc Newcastle sygdomsvirus-bårne fuglevacciner
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN106995488A (zh) * 2011-06-20 2017-08-01 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原
SG11201404653UA (en) 2012-02-07 2014-09-26 Univ Pittsburgh Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CN104144941B (zh) 2012-02-13 2017-06-09 高等教育联邦系统-匹兹堡大学 以计算方式优化的人和禽h5n1流感的广泛反应性抗原
HK1212708A1 (zh) 2012-11-27 2016-06-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education H1n1流感的計算優化的寬反應性抗原

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506272A (ja) * 2007-11-12 2011-03-03 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア インフルエンザウイルスの複数のサブタイプに対する新規ワクチン
WO2012036993A1 (en) * 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF INFECTIOUS DISEASES, vol. 205, JPN6016045951, 23 March 2012 (2012-03-23), pages 1562 - 1570, ISSN: 0003646441 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519085A (ja) * 2018-03-28 2021-08-10 サノフィ パスツール インコーポレイテッド ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法
JP7329530B2 (ja) 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法

Also Published As

Publication number Publication date
IN2014DN07399A (cg-RX-API-DMAC7.html) 2015-04-24
AU2013240365A1 (en) 2014-10-23
RU2639551C2 (ru) 2017-12-21
CA2868330A1 (en) 2013-10-03
WO2013148164A1 (en) 2013-10-03
KR20150004800A (ko) 2015-01-13
HK1203522A1 (en) 2015-10-30
US20150017196A1 (en) 2015-01-15
US9212207B2 (en) 2015-12-15
EP2831094A4 (en) 2015-10-14
BR112014023900A2 (pt) 2020-11-24
US20160279226A1 (en) 2016-09-29
MX345150B (es) 2017-01-18
US9555095B2 (en) 2017-01-31
EP2831094A1 (en) 2015-02-04
AU2013240365B2 (en) 2017-03-30
RU2017141447A (ru) 2019-02-13
SG11201406153XA (en) 2014-10-30
MX2014011387A (es) 2014-10-14
EP2831094B1 (en) 2018-06-13
CN104395336A (zh) 2015-03-04
RU2014142785A (ru) 2016-05-20
MY166953A (en) 2018-07-25
CN104395336B (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
JP6113155B2 (ja) 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
JP6175452B2 (ja) ヒトおよびトリｈ５ｎ１インフルエンザのための、計算で最適化した反応性の広い抗原
US9555095B2 (en) Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses
JP6336915B2 (ja) 計算で最適化した広い反応性を示すｈ３ｎ２、ｈ２ｎ２、およびｂ型インフルエンザウイルスの抗原
JP2018183149A (ja) Ｈ１ｎ１インフルエンザに対する計算で最適化した広い反応性を示す抗原
HK1203523B (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170925